Description of the portfolio company
ArkeaBio is a Boston-based start-up that is developing a vaccine to reduce methane emissions from livestock. The sector’s emissions are significant (~6% of total greenhouse gas emissions), but current mitigation agents have a long time to reach the market, targeting only a small population of animals or are expensive.
Investment rationale
In our efforts to reduce the climate impact of the current food system, we focus on alternatives to animal protein as well as solutions that make animal protein production more sustainable without negatively impacting animal welfare. In our search for solutions that can reduce the footprint of livestock farming and are applicable in all feeding systems, ArkeaBio emerged as a groundbreaking solution. Their cost-effective, easy-to-deploy, and high-quality vaccines have the potential to be a critical tool as part of the broader set of solutions that enable the transition of food systems.